Liver cancer

2L+, second line or later; HCC, hepatocellular carcinoma; IV, intravenous; QxW, every x weeks.

1. Opdivo^® (nivolumab). Hong Kong Prescribing Information; Hong Kong: Bristol-Myers Squibb; 2023.